Mitsubishi Chemical Holdings Corp. is considering acquiring the world’s second-largest pharmaceutical capsule maker from a U.S. investment fund to bolster its drug business, sources said Tuesday.
Mitsubishi Chemical seeks to turn Qualicaps Co. in Nara Prefecture into a subsidiary at a cost of some ¥50 billion.
Since Mitsubishi Chemical’s core petrochemical business faces competition posed by cheap imports from China and other countries, the firm seeks to shore up its operations by focusing more on drug-related businesses.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.